MyCare quickly provides objective information, and when used in combination with other clinical information, may help you make better-informed treatment decisions and enhance shared decision making between you and your patient.
For many physicians, blood level monitoring has become part of standard care. Every patient responds differently to a certain dose, and this can change over time due to external factors like smoking. Establishing a baseline level for a patient and monitoring it over time is important.
MyCare provides greater clarity on the causes of treatment failure (e.g., adherence, drug resistance, drug-drug interactions and drug metabolism) and may help distinguish medication non-response from lack of adherence.
MyCare tests provide doctors and patients insight into patient treatments, eliminating the trial and error approach of treatments. Both patients and caregivers feel that testing every time they go to the doctor’s appointment is ideal.
Psychiaters around the world were complaining about the turnaround time of a laboratory test. Typically, analysis by LCMS-MS can take 3 to 10 days. This after the fact information misses its impact.
A finger prick blood test, allows for the blood level values to be available at the moment of consultation, and help to make a better treatment decisions, or have a discussion about adherence.
For many labs the rapid test also saves costs, as laboratory tests are not cheap.
The Insite measures the blood levels of the most common antipsychotic drugs along with frequently tested HbA1c. Taking the test is simple. Similar to a blood glucose test, it requires only a single drop of blood from a finger. It generates lab quality results at the point of care in approximately 7 minutes. You can watch the installation and training video here.
Clozapine, Total Risperidone, Quetiapine, Total Aripiprazole, Olanzapine, and Paliperidone assays, and HbA1c
For scientific data we refer to the independent validation study on the clozapine Insite assay by IoPPN (Maudsley Kings College London), presented at ECNP 2019. (n=304, R=0,9, CV <10%, linear across the range)
↓ 2019 ECNP Poster – Point of Care Testing for Clozapine (validation study IoPPN)
|MCI-EUR||MyCare Insite Instrument with European Power Supply (Saladax)|
|CLZ-MCI||MyCare Psychiatry Clozapine Test for Saldax Insite system|
|RSP-MCI||MyCare Psychiatry Total Risperidone Test Saldax Insite system|
|PAL-MCI||MyCare Psychiatry Paliperidone Test Saldax Insite system|
|ARI-MCI||MyCare Psychiatry Total Aripiprazole Test for Saldax Insite system|
|QTP-MCI||MyCare Psychiatry Quetiapine Test for Saldax Insite system|
|OLZ-MCI||MyCare Psychiatry Olanzapine for Saldax Insite system|
|MCP2-CON||MyCare Psychiatry Control Set 2, for Insite (Total Aripiprazole, Clozapine, Quetiapine, Olanzapine)|